Mayapada HOPE 2026 brings together global and local oncology expertise to advance more precise, sophisticated and personalised cancer care, in line with the latest developments in global oncology practices.
Advances in diagnostic nuclear medicine, robotic surgery and increasingly targeted cancer therapies have become essential components of modern oncology, creating new opportunities for more precise and personalised cancer care. Bringing these advancements closer to patients in Indonesia, Mayapada Healthcare hosted Mayapada HOPE (Holistic Oncology for Patient-Centred Excellence) 2026, under the theme ‘Shaping the Future of Cancer Care: Precision in Every Decision’.
Mayapada HOPE 2026 brought together international oncology experts, as well as specialists and subspecialists from Mayapada Hospital, to discuss the latest advancements in cancer care, from precision oncology and robotic surgery to innovative therapies, nuclear medicine and theranostics. The event also served as a platform for strategic dialogue with partners from the corporate, insurance and community sectors, while highlighting the capabilities of Mayapada Hospital’s Oncology Centre in delivering cancer care that meets international standards. This commitment is reflected in its integrated approach, combining multidisciplinary medical expertise, advanced medical technologies and comprehensive patient support to deliver precise, personalised and coordinated care.
Navin Sonthalia, President Director and CEO of Mayapada Healthcare, stated that the adoption of modern oncology practices is part of Mayapada Healthcare’s strategy to deliver internationally recognised cancer care that is increasingly accessible to the Indonesian public.
“Indonesia has highly skilled doctors. Our role is to ensure that their expertise is supported by the latest medical technology, multidisciplinary collaboration, and access to advances in global clinical practice. Through Mayapada HOPE 2026, we demonstrate the capabilities of Mayapada Hospital’s Oncology Centre in delivering increasingly advanced, precise, and personalised cancer care, enabling people to access high-quality services here in Indonesia,” said Navin.
Prof. Dr Ikhwan Rinaldi, Sp.PD-KHOM, a Medical Haematology-Oncology Consultant and member of the Tumour Board at Mayapada Hospital’s Oncology Centre, explained that modern cancer care increasingly emphasises precision oncology, which involves selecting treatments based on the characteristics of the cancer and each patient’s individual condition.
“Two patients with the same type of cancer may not necessarily require the same treatment. Treatment decisions must take into account the cancer stage, tumour characteristics, and the patient’s overall health. This is why multidisciplinary collaboration through a Tumour Board is essential to determining the most appropriate treatment strategy, ranging from surgery, chemotherapy, targeted therapy, and immunotherapy to combinations of treatments tailored to each patient’s needs,” explained Prof. Ikhwan.
Advances in cancer care are also driven by minimally invasive surgical techniques, involving procedures performed through small incisions and supported by robotic technology. These innovations enable doctors to perform complex procedures with enhanced visualisation and greater precision in instrument control.
Prof. (Dr) Sanjai Kumar Addla, MRCS, MD, FRCS (Uro), from Apollo Hospitals Jubilee Hills, Hyderabad, India, who has performed more than 1,000 robotic surgical procedures for urological conditions, emphasised that precision oncology, as part of global cancer care standards, prioritises multidisciplinary collaboration among doctors, including the adoption of robotic surgery, which offers significant clinical benefits and broader strategic value.
“Indonesia has no shortage of highly skilled doctors. Their expertise must be supported by the latest medical technologies to ensure they can deliver care in line with evolving global standards. Robotic surgery is no longer a technology of the future; it has become an integral part of modern surgical practice. The availability of this technology at Mayapada Hospital enables doctors to perform complex procedures with enhanced visualisation and more precise instrument control, while making globally aligned surgical advancements increasingly accessible to Indonesian patients,” explained Prof. Sanjai at Mayapada HOPE 2026.
On the same day, Mayapada Hospital Jakarta Selatan successfully performed a da Vinci Xi robot-assisted mastectomy (surgical removal of breast cancer), led by Dr Bayu Brahma, Sp.B.Subsp.Onk(K). The surgical plan was also discussed with Clinical Associate Professor Mok Chi Wei, a surgical expert from Changi General Hospital, Singapore, who was among the speakers at Mayapada HOPE 2026.
The procedure was successfully performed through a single small incision, helping to minimise visible surgical scarring while preserving the breast skin and nipple, as well as supporting patients’ appearance and confidence following surgery. This achievement reflects Mayapada Hospital’s Oncology Centre’s commitment to continuously advancing cancer care through the adoption of cutting-edge surgical technologies. These capabilities were also showcased to strategic partners from the corporate, insurance and community sectors as part of Mayapada HOPE 2026.
During the panel discussion titled ‘The Evolution of Cancer Surgery: Advancing Patient Outcomes Through Innovation’, Prof. Mok Chi Wei stated, “Advances in minimally invasive surgery and robotic technology have significantly transformed cancer care, including breast cancer surgery, which can now be performed with greater precision while helping preserve breast shape and maintain patients’ quality of life. The successful robot-assisted surgery at Mayapada Hospital demonstrates the Oncology Centre team’s clinical expertise in adopting advanced surgical innovations in line with the latest developments in global oncology practices,” said Prof. Mok Chi Wei.
Beyond surgery, nuclear medicine and theranostics play an increasingly important role in improving cancer detection and enabling more targeted treatments. This was highlighted by Dr Ngam Pei Ing from National University Hospital, Singapore, in her presentation, ‘Advancing Precision Cancer Care Through Theranostics’.
“Positron Emission Tomography (PET) Scan and Single Photon Emission Computed Tomography (SPECT) Scan provide doctors with critical insights into a patient’s condition and the extent of cancer spread, serving as a foundation for determining the most appropriate treatment. Theranostics, meanwhile, offers new opportunities for more targeted therapies tailored to the specific characteristics of each patient’s disease. The availability of PET and SPECT Scan technologies at Mayapada Hospital marks an important milestone in expanding access to advanced diagnostics for people across Indonesia and supporting more precise cancer care. It enables patients to access services aligned with global oncology standards right here in their own country,” explained Dr Ngam.
The successful implementation of precision oncology requires more than advanced technology and medical expertise. It also demands integrated, continuous care throughout every stage of a patient’s treatment journey. To support this approach, Mayapada Hospital has established a Tumour Board, bringing together specialists and subspecialists from various medical disciplines to develop the most appropriate treatment strategies. This is further strengthened by standardised clinical pathways, Patient Navigators who guide patients and their families throughout the treatment process, and continuous service quality monitoring to optimise clinical outcomes.
Dr Dini Handayani, Chief Medical Officer of Mayapada Healthcare, emphasised that precision in cancer care means ensuring that every medical decision is tailored to the right patient at the right time.
“Precision in cancer care means ensuring that every medical decision is right for the right patient at the right time. Through our Tumour Board, standardised care pathways, and Patient Navigator support, we ensure continuity across every stage of treatment, from initial examinations and treatment selection to ongoing follow-up care. This allows us to deliver personalised and continuous care that addresses each patient’s individual needs. This is the essence of Mayapada HOPE 2026: translating global advances in oncology into tangible improvements in treatment outcomes and the quality of life of patients in Indonesia,” concluded Dr Dini.